AlenMed

Treatment in Germany

EN

Mon–Fri 9:00–21:00 · Sat 10:00–18:00 (CET)
+49 176 61975550 — daily until 23:00

Novel Drug Repinatrabit Reduces Phenylalanine Levels in Phenylketonuria

Neurology

An international research collaboration, featuring the active participation of Prof. Dr. Ania C. Muntau, Director of the Clinic for Paediatric and Youth Medicine at the Universitätsklinikum Hamburg-Eppendorf (UKE), has identified a promising pharmacological approach for managing phenylketonuria. The scientific team demonstrated that the investigational active compound Repinatrabit can significantly lower the concentration of the amino acid phenylalanine in the blood plasma of adult patients diagnosed with this metabolic condition. The findings were recently published in the prestigious New England Journal of Medicine. This scientific milestone introduces a fresh clinical perspective for individuals living with this hereditary metabolic disorder, offering potential alternatives to traditional management strategies.

Phenylketonuria and the Daily Challenge of Metabolic Control

Phenylketonuria and the Daily Challenge of Metabolic Control

Phenylketonuria is a rare inherited metabolic disorder caused by mutations that result in a deficiency or complete absence of the hepatic enzyme phenylalanine hydroxylase. Under normal physiological conditions, this essential enzyme is responsible for converting the essential amino acid phenylalanine, which is present in dietary proteins, into tyrosine. When this enzymatic pathway is disrupted or non-functional, ingested phenylalanine cannot be properly processed and begins to accumulate in abnormally high amounts throughout the bloodstream and body tissues. Excessive levels of phenylalanine circulating in the blood exert direct neurotoxic effects on the developing and mature central nervous system.

If left unmanaged or inadequately treated from infancy, the accumulation of phenylalanine leads to severe neurological impairment, profound intellectual disability, irreversible brain damage, movement disorders, and emotional disturbances. The condition manifests early in infancy as soon as protein intake begins through breast milk or conventional infant formula. Because the metabolic block prevents natural breakdown, affected individuals must adhere strictly to a rigorous, low-protein diet throughout their entire lives to avoid toxic accumulation. This dietary intervention requires eliminating meat, fish, dairy products, eggs, nuts, legumes, and conventional wheat products.

Maintaining such a restrictive dietary regime imposes an enormous physical, psychological, and social burden on affected individuals and their families. Patients must painstakingly measure and log every gram of food consumed while relying on specialized, synthetic amino acid formula supplements free of phenylalanine to meet basic nutritional requirements. As pediatric patients transition into adolescence and adulthood, strict compliance with dietary restrictions frequently becomes difficult to maintain alongside professional and social commitments. Consequently, discovering reliable pharmacological treatments that lower systemic phenylalanine levels remains a major priority in modern clinical genetics.

Current Diagnostic Standards and Medical Management in Germany

Current Diagnostic Standards and Medical Management in Germany

In specialized medical centers across Germany, the diagnosis of phenylketonuria is achieved swiftly and reliably through standardized nationwide newborn screening programs. Within the first few days of life, a tiny sample of heel-prick blood is collected and analyzed using advanced tandem mass spectrometry. This sophisticated analytical technique allows laboratory specialists to detect elevated concentrations of phenylalanine long before any structural damage to the central nervous system occurs. Establishing an early diagnosis is critical, as immediate dietary intervention prevents the onset of irreversible cognitive deficits and supports normal neurodevelopment.

The cornerstone of therapeutic management in Germany continues to be an individually tailored, highly controlled diet that strictly limits natural protein consumption. Medical specialists design meticulous nutritional plans that supplement minimal natural protein allowances with tailored synthetic amino acid mixtures containing essential vitamins and trace elements. Continuous medical supervision involves frequent monitoring of blood phenylalanine concentrations. For adult patients undergoing treatment in Germany, the established therapeutic target range for phenylalanine in blood plasma is kept between 120 and 600 micromol per liter to protect neurological function.

Although dietary control is highly effective when maintained perfectly, keeping blood amino acid levels within safe boundaries requires lifelong monitoring by specialized metabolic physicians and metabolic dietitians. Metabolic centers in Germany combine routine blood chemistry analyses with comprehensive neurological evaluations and nutritional counseling. Nevertheless, because dietary management does not address the underlying transport or enzymatic mechanics, the development of pharmacological therapies capable of directly modulating amino acid levels represents a long-awaited advancement in metabolic medicine.

Repinatrabit and New Clinical Horizons in Germany

Repinatrabit and New Clinical Horizons in Germany

The innovative therapeutic concept evaluated by the international research group, including Prof. Dr. Ania C. Muntau from Universitätsklinikum Hamburg-Eppendorf (UKE), targets amino acid dynamics through a novel pharmacological mechanism. The investigational compound Repinatrabit functions by specifically inhibiting the transport protein SLC6A19, which plays a major role in the intestinal absorption and renal reabsorption of neutral amino acids. By inhibiting the action of SLC6A19, Repinatrabit effectively reduces the uptake of phenylalanine from the gastrointestinal tract and limits its reabsorption in the kidneys, thereby encouraging systemic clearance.

The clinical investigation, authored by Harding CO, Longo N, McNutt M et al. and published in the New England Journal of Medicine (2026, DOI: 10.1056/NEJMc2514812), presented compelling results from a Phase II clinical trial. The study focused on adult patients with phenylketonuria who presented with baseline blood plasma phenylalanine levels exceeding 600 micromol per liter. Oral administration of Repinatrabit produced a marked reduction in plasma phenylalanine levels, successfully bringing patients within or significantly closer to the recommended therapeutic target range of 120 to 600 micromol per liter.

Building upon these encouraging Phase II results, a comprehensive Phase III clinical trial involving both adolescent and adult patients is currently underway, alongside extended long-term trials designed to assess multi-year safety and sustained efficacy. The Kinder-UKE team is actively participating in these ongoing clinical studies. For international patients seeking expert consultation or treatment in Germany, these scientific developments signal a prospective evolution in metabolic care. During medical consultations at German university hospitals, patients can discuss their metabolic profile, explore optimized traditional regimens, and inquire about eligibility for modern pharmacological studies.

Source: Universitätsklinikum Hamburg-Eppendorf

All news